Effects on Endogenous Metabolites Following the Administration of Methapyrilene: A Data-Dependent Acquisition Workflow Using the Xevo™ MRT Mass Spectrometer

Importance of the Topic

Pharmacometabodynamics investigates reversible, time-dependent changes in endogenous metabolites induced by drug administration, offering critical insights into drug action and toxicity mechanisms. Methapyrilene, an H1-receptor antagonist linked to drug-induced liver injury, serves as a model to explore how dosing regimens affect metabolic phenotypes.

Objectives and Study Overview

This study aimed to characterize urinary metabolomic alterations in rats over six days following oral administration of methapyrilene at varying doses, demonstrating a data-dependent acquisition (DDA) workflow on the Xevo MRT mass spectrometer to achieve high-confidence metabolite identification.

Methodology and Instrumentation

Wistar rats (n=18) received daily oral doses of methapyrilene (0, 10, or 150 mg/kg) for five days. Urine was collected at defined intervals, protein-precipitated with acetonitrile/methanol, centrifuged, and diluted before analysis.

Reversed-phase UPLC employed a 5.0 min gradient (50–99% acetonitrile) at 0.6 mL/min. Mass spectrometric data were acquired in DDA mode (20 Hz MS; 50 Hz MS/MS) with dynamic exclusion. Instrumentation included:

• ACQUITY Premier UPLC System
• Xevo MRT Mass Spectrometer

Data conversion to mzML and processing in MS-DIAL encompassed peak picking, alignment, normalization, principal component analysis (PCA), analysis of variance (ANOVA), hierarchical clustering, and compound identification against a spectral library of authentic standards.

Key Results and Discussion

The workflow detected 18 653 features. PCA revealed clear time-dependent metabolic shifts and cage effects; drug-related signals were excluded to focus on endogenous changes. The top 25 discriminatory features included amino acids, organic acids, and nucleosides. Cholic acid identification demonstrated high MS/MS coverage and sub-ppm mass accuracy. Tightening mass tolerances from 5 ppm/2 ppm to 1 ppm/1 ppm reduced database hits from 8 869 to 4 693 candidates. A dipeptide feature (m/z 245.1859) was narrowed from 48 to 4 possible structures and confidently assigned as isoleucyl-isoleucine based on a diagnostic fragment ion at m/z 130.0505.

Benefits and Practical Applications

• Rapid DDA acquisition yields rich fragmentation data for structural elucidation.
• High mass resolution and accuracy minimize false positives in database searches.
• Integration with MS-DIAL ensures a streamlined, reproducible workflow for large-scale metabolomic studies.

Future Trends and Potential Applications

Advancements in mass spectrometry speed and resolution will further enhance detection of low-abundance metabolites. Combining pharmacometabodynamic profiling with multi-omics and machine learning holds promise for personalized drug safety assessments and mechanistic toxicology studies.

Conclusion

The optimized DDA workflow on the Xevo MRT mass spectrometer, coupled with fast UPLC and robust data processing, delivers high-confidence metabolite identifications. This approach enables in-depth characterization of drug-induced metabolic dynamics and supports improved toxicological evaluation.

References

1. Molloy et al. The Pharmacometabodynamics of Gefitinib after Intravenous Administration to Mice: A Preliminary UPLC-IM-MS Study. Metabolites. 2021;11(6):379.
2. Graichen et al. Effects of methapyrilene on rat hepatic xenobiotic enzymes and liver morphology. Fundam Appl Toxicol. 1985;5:165–174.
3. Tsugawa et al. MS-DIAL: data-independent MS/MS deconvolution for comprehensive metabolome analysis. Nat Methods. 2015;12:523–526.